Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice
Scientific Reports Volume 6
Page 20157-
published_at 2016-01-28
アクセス数 : 618 件
ダウンロード数 : 95 件
今月のアクセス数 : 5 件
今月のダウンロード数 : 0 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00048635
File |
SciRep_6_20157.pdf
4.5 MB
種類 :
fulltext
|
Title ( eng ) |
Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice
|
Creator |
Kushiyama Akifumi
Sakoda Hideyuki
Nakatsu Yusuke
Iizuka Masaki
Taki Naoyuki
Fujishiro Midori
Nishimura Fusanori
Katagiri Hideki
Asahara Takashi
Yoshida Yasuto
Chonan Osamu
Encinas Jeffery
|
Source Title |
Scientific Reports
|
Volume | 6 |
Start Page | 20157 |
Abstract |
Resistin-like molecule β (RELMβ) reportedly has multiple functions including local immune responses in the gut. In this study, we investigated the possible contribution of RELMβ to non-alcoholic steatohepatitis (NASH) development. First, RELMβ knock-out (KO) mice were shown to be resistant to methionine-choline deficient (MCD) diet-induced NASH development. Since it was newly revealed that Kupffer cells in the liver express RELMβ and that RELMβ expression levels in the colon and the numbers of RELMβ-positive Kupffer cells were both increased in this model, we carried out further experiments using radiation chimeras between wild-type and RELMβ-KO mice to distinguish between the contributions of RELMβ in these two organs. These experiments revealed the requirement of RELMβ in both organs for full manifestation of NASH, while deletion of each one alone attenuated the development of NASH with reduced serum lipopolysaccharide (LPS) levels. The higher proportion of lactic acid bacteria in the gut microbiota of RELMβ-KO than in that of wild-type mice may be one of the mechanisms underlying the lower serum LPS level the former. These data suggest the contribution of increases in RELMβ in the gut and Kupffer cells to NASH development, raising the possibility of RELMβ being a novel therapeutic target for NASH.
|
Language |
eng
|
Resource Type | journal article |
Publisher |
Nature Publishing Group
|
Date of Issued | 2016-01-28 |
Rights |
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
|
Publish Type | Version of Record |
Access Rights | open access |
Source Identifier |
[ISSN] 2045-2322
[DOI] https://doi.org/10.1038/srep20157
[PMID] 26818807
|